Jeffrey Abbey joined Argos Therapeutics in September 2002. Before joining Argos, Mr. Abbey was Vice President of Business Development and Finance for Internet Appliance Network (IAN), a venture-backed information technology company based in New York City. Prior to joining IAN, he was a partner in Eilenberg and Krause, a boutique corporate law firm, where he acted as business counsel for a number of life sciences and other emerging technology companies. Mr. Abbey has extensive experience in structuring and negotiating licenses, joint ventures and other technology transfer agreements, as well as mergers, acquisitions and financing transactions. He holds an A.B. in Mathematical Economics from Brown University and received an M.B.A. and J.D. from the University of Virginia.

Daniel Adams became CEO of Protein Sciences in 1995. He has previously founded and managed biopharmaceutical companies that have a combined market value of over $10 billion. He co-founded Biogen (OTC-BGEN) and served as its first President and CEO, founded and was CEO of Advanced Genetic Sciences Inc. ("AGS"), and co-founded Plant Genetic Systems in 1982. Dan holds a BA degree in Chemistry from Cornell University and a JD magna cum laude from New York University School of Law.

Garo H. Armen is chairman and chief executive officer of Antigenics Inc., the biotechnology company he cofounded with Pramod Srivastava in 1994. From mid-2002 through 2004, he was chairman of the board of directors for the biopharmaceutical company Elan Corporation plc. Dr. Armen also serves on the board of directors of Color Kinetics Inc., a company that designs, markets and licenses intelligent solid-state lighting systems. Dr. Armen is also the founder and president of the Children of Armenia Fund (COAF), a charitable organization established in 2000 that is dedicated to the positive development of the children and youth of Armenia.

Lewellys F. Barker is currently Senior Medical Advisor with the Aeras Global TB Vaccine Foundation in Rockville, MD. His major professional interest is in the prevention, treatment and control of infectious diseases with vaccines, drugs and diagnostic tests. He has worked as a bench and clinical scientist and served as a senior manager with the NIH/NIAID’s Division of AIDS and NIH’s Division of Biologics Standards, the FDA’s Bureau of Biologics, the American Red Cross, and Cary Pharmaceuticals, Inc. His responsibilities have encompassed product development, regulation, medical and public health applications of biologics, pharmaceuticals and diagnostics. He has published extensively on his work in preclinical and clinical research on disease detection, epidemiology, risk assessment, treatment and prevention of infectious diseases. He has served on a number of boards and committees and is a past president of the National Health Council and the International Society of Blood Transfusion. He graduated from Princeton University (BA) and the Johns Hopkins University School of Medicine (MD) and School of Hygiene and Public Health (MPH). He is married to Eileen F. Barker, MD, MPH, who is a retired career medical officer with the FDA. They live in Chevy Chase, MD, and have two daughters, Robin, a pediatric nurse, and Lillian, an architect, and a son, Colin, who is in training in cardiology, and four granddaughters. In his leisure time Lew enjoys bicycling, kayaking, photography, reading and gardening.

SETH BERKLEY, President, CEO and founder of the International AIDS Vaccine Initiative, a global not-for-profit organization, operational in 24 countries, working to ensure the development of safe, effective, accessible, preventive HIV vaccines for use throughout the world. He is a medical doctor specializing in infectious disease epidemiology and international health. Prior to founding IAVI in 1996, Dr. Berkley was the Associate Director of the Health Sciences Division at The Rockefeller Foundation. He has worked for the Center for Infectious Diseases of the U.S. Centers for Disease Control, the Massachusetts Department of Public Health, and for the Carter Center, where he was assigned as an epidemiologist at the Ministry of Health in Uganda. In Africa, Dr. Berkley played a key role in Uganda’s national HIV sero-survey and helped develop its National AIDS Control programs.

Bob co-founded Ichor and led the team that invented the TriGrid platform technology and established its proof of concept. Throughout his business and professional career, he has developed an extensive background in the life sciences. He is a proven entrepreneur with experience managing and directing innovative technology-based companies. Prior to founding Ichor, he was president and founder of Bernard Foods, Inc., an innovative, technology-based food business that was acquired by Nestle in 1992. Bob served as Nestle vice president, new business development until founding Ichor. Bob received his degree in Mechanical and Electrical Engineering from Louisiana State University.

Dr. CALEY is Director of Business Development at AlphaVax, Inc., a privately-held biotechnology company based in Research Triangle Park, North Carolina. She obtained a PhD in Microbiology and Immunology from the University of North Carolina in 1999 where she contributed to the development of the alphavaccine platform system. Upon completion of her doctoral work, she joined AlphaVax as a Research Scientist, subsequently moving into the business development and licensing group in 2001. At AlphaVax she is directly involved in in/out-licensing activities, coordination of external R&D programs with academic/corporate partners and grant/investment funding. She is the Project Team Leader for AlphaVax’s lead commercial program for CMV.

Joe Cohen is the co-inventor and original patent holder of the RTS,S/AS02A malaria vaccine. In January 2005, he has been appointed Vice President R&D for GSK Bio’s Emerging Diseases & HIV Vaccine Program, responsible for the development of vaccines against Malaria, TB and HIV. In 1984 Joe joined GSK Biologicals and took over the leadership of the company’s malaria vaccine program three years later. Joe has spent 20 years working to expand upon the “fundamental insight” he and his GSK colleagues had in 1987 – that combining the recombinant technology in GSK’s Hepatitis B vaccine with parts of the CSP antigen derived from the malaria pathogen and adequately formulating the resulting hybrid protein could produce a successful malaria vaccine. In 1999, Joe helped to create GSK Bio’s new program for vaccines for emerging diseases, which include Malaria, TB & HIV.

The acquisition of knowledge about the risks and safety of a drug product should continue throughout its life cycle. Proactive risk management has major benefits for patients, health care professionals, regulators and manufacturers. Regulatory agencies are requiring a proactive approach to risk management for all products, especially vaccine products intended for use in healthy populations. The development of the risk management plan for Gardasil® is discussed as an example of pharmacovigilance planning for a new vaccine. Adrian Dana is Senior Director of Clinical Risk Management & Safety Surveillance at Merck. Her responsibilities include risk management and safety for numerous vaccine products. Since joining Merck she has been responsible for developing the Risk Management Plans for three initial vaccine filings and several supplemental vaccine filings. Prior to joining Merck, Dr. Dana was in Global Medical Affairs at Wyeth, first as a director in anti-infectives, later as Therapeutic Area Director for Vaccines.

Jean began his venture capital career in 1971 in Paris, France with Sofinnova and started its very successful American subsidiary, Sofinnova, Inc. in 1976 in San Francisco. In 1979, he formed Burr, Egan, Deleage & Co., with Craig Burr and William Egan. During the 1980s and 1990s, BEDCO was a prominent, diversified venture firm. He co-founded Alta in 1996. Jean is an industry leader in biotechnology; he had the vision to start the Alta BioPharma family of funds, one of the very first venture capital initiatives to fund later stage life sciences companies. He was an early investor in many of the leading companies in the field today, including Genentech, Chiron, and Cephalon. Jean holds a Masters Degree in Electrical Engineering from the École Supérieure d’Electricité and a Ph.D. in Economics from the Sorbonne. In 1993, Jean was awarded the Legion of Honor by the French government in recognition of his career accomplishments.

• 20 years of clinical vaccine development experience with Merck, GSK and Chiron. • Entrepreneurial drive and vision and a dynamic and charismatic leader.

Gary Dubin graduated from the University of Pennsylvania School of Medicine in 1983. After completing his internship and residency at the University of Colorado and research fellowships in Virology and Infectious Diseases at the University of Pennsylvania he joined the faculty of Infectious Diseases in the Department of Medicine at University of Pennsylvania in 1991. Dr. Dubin joined GlaxoSmithKline Biologicals in 1995 and has lead the development program for its HPV vaccine program since its inception as well as the HSV vaccine development program. Dr. Dubin currently serves as Vice President and Director for Clinical Development, Prophylactic Vaccines, North America at GlaxoSmithKline. He is also Adjunct Associate Professor of Medicine at the University of Pennsylvania.

Peter Dull MD is the Head of Development of Meningococcal Conjugate Vaccines at Novartis Vaccines and Diagnostics where he leads clinical development activities and regulatory strategies for the MenACWY and Menjugate vaccine programmes. He is also the Head of Epidemiology, providing epidemiological support for Novartis vaccine development programmes. He joined Chiron Vaccines (now Novartis Vaccines and Diagnostics) in 2004 and is currently based in Siena, Italy. He completed his Internal Medicine training at Oregon Health Sciences University in Portland, OR, USA after attending medical school at the University of Wisconsin-Madison. After training as an Epidemic Intelligence Officer in the Meningitis and Special Pathogens Branch at CDC in Atlanta, GA, he trained in his Infectious Diseases Subspecialty at Emory University in Atlanta, GA. His research at CDC has included investigations of the anthrax bioterrorist attacks, immune response to inhalational and cutaneous anthrax and surveillance post-9/11 World Trade Center attacks in 2001. His CDC work also included outbreak investigations of meningococcal meningitis and epizootic anthrax in the USA and Africa, and molecular diagnostics of bacterial meningitis.

Dr. Krishna M. Ella pursued his early education in India and acquired his Postgraduate Degree in Agricultural Sciences with Distinction and Gold Medals. After working with Sandoz (I) Ltd and Bayer, he moved to the US for Higher Studies on a Rotary Foundation Scholarship. Dr. Ella was awarded his Doctorate from the University of Wisconsin-Madison in Molecular Biology. He received the National Research Service Award from the National Institute of Health, Bethesda, Maryland and became a part of the Research faculty at the Medical University of South Carolina- Charleston. As a scientist par international standard, well versed in the Plant/Human/Yeast systems, Dr. Ella has more than 30 scientific publications to his credit in peer reviewed academic journals. His expertise in Gene Expression Systems has been well acclaimed and demonstrated, internationally. He is a member of various high level Commissions viz., X Five Year Plan – Biotechnology, Government of India, Co-chair, Human Resources & Innovation, National Biotech Policy, GoI (2004-05), Co-chair, High Technology Cooperation Groups (HTCG) – Indo-US Governments, National Task Force – Industrial Biotechnology, GoI and member of Confederation of Indian Industry's National Council on IPR. Chairman of Federation of Indian Chambers of Commerce and Industry (FICCI) – Biotech Committee, he is also the Advisor for many State Governments on Biotechnology. Dr. Ella is the first recipient of the Best Entrepreneur of the Year, 2003. He founded and established Bharat Biotech International Limited in 1996 along with his wife Suchitra Ella. The Company today, is on the forefront of Indian Biotechnology engaged in R&D, manufacturing and marketing of vaccines and biotherapeutics.

Dr. Ronald Ellis has 25 years of industry experience in research and development of vaccines and biologics. He has championed or led R&D efforts on a wide range of viral and bacterial vaccines from discovery or in-licensure through early and advanced development as well as to product licensure and launch – including several vaccines on the market – those for human papilloma virus, rotavirus, varicella, hepatitis B, and Haemophilus influenzae type b. He is Editor-in-Chief of the peer-reviewed journal Human Vaccines, launched in 2005.

Mr. Erck applies his 25 years of management experience in the healthcare and biotechnology industry (Baxter International, Procept and Integrated Genetics) to shepherd the development and commercialization of Iomai technology. In addition to successfully negotiating major alliances with pharmaceutical and biotechnology companies and bringing products into clinical trials, as CEO he has managed the process of developing companies from private funding through public offerings. Mr. Erck received his B.S. from the University of Illinois and an M.B.A. from the University of Chicago.

Dr. Fahim is President and Chief Executive Officer of Nabi Biopharmaceuticals. He most recently served as Chief Operating Officer and General Manager. In May 2003, he was named Senior Vice President, Research, Technical and Manufacturing Operations of Nabi Biopharmaceuticals and was Vice President of Vaccine Manufacturing Operations upon joining Nabi Biopharmaceuticals in March 2003. His career includes 14 years with Aventis Pasteur from 1987 to 2001, where he was instrumental in developing several vaccines from early research to marketed products. During his tenure there, he held the positions of Vice President, Industrial Operations; Vice President, Development, Quality Operations and Manufacturing; Director of Product Development; and head of bacterial vaccines research/research scientist. During the year prior to joining Nabi Biopharmaceuticals, Dr. Fahim was an independent consultant, working with Aventis Pasteur and other companies worldwide on projects that included manufacturing, process improvement, quality operations and regulatory issues. From 2001 to 2002, he served as President and Chief Operating Officer of Lorus Therapeutics, Inc., a Toronto-based biopharmaceutical company focused on the research and development of cancer therapies. Dr. Fahim received his Ph.D. in Biochemistry from the University of Toronto.

Sammy Farah joined Versant Ventures in 2007 and specializes in biotechnology investing. He is currently a board observer at Amira Pharmaceuticals, Jazz Pharmaceuticals, Kythera Biopharmaceuticals, Sentient Pharmaceuticals and Trius Therapeutics. Prior to joining Versant, Sammy spent 12 years at Merck & Co., Inc., where he served in several roles. Most recently, Sammy was a Scientific Liaison in the External Scientific Affairs department with primary focus on identifying and evaluating technology acquisition and research opportunities, structuring and negotiating licensing agreements, and building and managing relationships with key external partners for the biologics and oncology franchises. Previously, Sammy worked in the Vaccine Technology and Engineering department at Merck where he managed manufacturing facility start-up, process development and technical support for a number of vaccines including hepatitis A, pneumococcal polysaccharide and haemophilus influenzae type b. Sammy earned his Bachelor of Science in Chemical Engineering from the Massachusetts Institute of Technology, Doctor of Philosophy in Biochemical Engineering from Stanford University and MBA from the Wharton School of Business.

Dr. Jessica Baker Flechtner is the Director of Immunology at Genocea Biosciences, Inc. At Genocea, Dr. Flechtner has been integral in establishing a functional laboratory for the new company and is leading Genocea’s research efforts to identify novel T cell antigens for inclusion in vaccines directed against a variety of infectious diseases. Prior to joining Genocea, Dr. Flechtner was an Immunology Consultant at Biovest International, where she was responsible for the generation of clinical assays to evaluate the efficacy of their autologous antibody-based vaccine in follicular lymphoma patients. Her industry experience also includes extensive preclinical vaccine development. As a scientist at Mojave Therapeutics, Inc. and Senior Scientist at Antigenics Inc., which acquired Mojave’s intellectual property, Dr. Flechtner developed protein and peptide-based vaccines and immunotherapies relevant to cancer, infectious disease, autoimmunity and allergy. Dr. Flechtner received her PhD in Cellular Immunology at the James A. Baker Institute for Animal Health at Cornell University’s College of Veterinary Medicine, and post-doctoral training at Dana-Farber Cancer Institute and Harvard Medical School.

Tony Ford-Hutchinson obtained his B.Sc. in Biochemistry from the University of Birmingham (1968), a M.Sc. in Molecular Enzymology from the University of Warwick (1969), and a Ph.D. in Biochemistry (1972) from the University of London. Tony joined Merck Frosst Canada in 1981 as Director of Pharmacology coming from Kings College Hospital Medical School, London, UK where he was a lecturer in the Chemical Pathology Department, having carried out research in the field of leukotrienes and prostaglandins. Following several promotions, he was appointed Vice-President of the Merck Frosst Research Laboratories in 1994 and in 1996 also took on additional responsibilities as the principal liaison between Merck Research Laboratories and Banyu Tsukuba Basic Research in Japan.

Dr Friedland has been Senior Director, Vaccines, Clinical R&D and Medical Affairs at GlaxoSmithKline Biologicals in North America since 2003. Prior to his present position, Leonard worked with Antiinfectives and Analgesics during a 2 year period at AstraZeneca from 2000-2002. Leonard has held several positions at long established Children’s hospitals during a 14 year career stretching back to 1987. In this time Leonard has taken up positions in the Children's Hospital of Philadelphia, St. Christopher's Hospital for Children, Cincinnati Children's Hospital Medical Center and Temple Children’s Hospital.

Gerard Gach is presently the Global Product Platform Director of GE Healthcare (GEHC) Life Science ReadyToProcess™ and Filtration business’ where his team is responsible for ready-to-use and membrane based products for GE business involved in bio processing division. He has previously served as Global Marketing Leader, for the Advanced Separations business of GE Infrastructure’s Water & Process division centered on novel membrane and chemical separation technology. His employment history includes over 25 years in the filtration / separations industry with GE, Osmonics, Koch Membrane Systems and Pall Corporation in capacities of R&D Supervisor, Sales and Sale Management and Business Development. Gerard has a BS from St. John’s University with a focus in Chemistry and further course studies in Marketing and Business Management.

After receiving her Pharm.D degree in 1982 and PhD (immunotoxicology, immunopharmacology) in 1985, Dr. Garçon spent 1 year in England as a postdoctoral research fellow (liposomes in vaccines) at the Royal free Hospital in London. She then spent 4 years in the United States (Baylor College of Medicine, Houston Texas, USA) first as postdoctoral research fellow, then as assistant professor, working on vaccine delivery systems and immunopotentiators. Dr Garçon joined SmithKline Beecham Biologicals –now GlaxoSmithKline- in 1990 where she set up the vaccine adjuvant and formulation group. She now is vice president, head of research and north America R&D; Her responsibilities encompasse basic immunology, formulation design and characterization, toxicology evaluation, research and clinical testing of human cell mediated immunity, biotechnologies (bioExperimentation, bio statistics, bio informatique). Expertise covers vaccinology from research to manufacturing, in particular immunology and immunological read-outs, formulation technology, analytical methods, animal experimentation and toxicology evaluation and testing.

Douglass Given, MD, PhD, MBA, is an Investment Partner at Bay City Capital and has been with the firm since October 2000. He was formerly Chief Executive Officer and a director of NeoRx, and Corporate Sr. Vice President and Chief Technical Officer of Mallinckrodt. Prior to Mallinckrodt, Dr. Given served as Chief Executive Officer and a director of Progenitor and Mercator Genetics. He held positions as Vice President at Schering Plough Research Institute, Vice President at Monsanto/G.D. Searle Research Laboratories, and Medical Advisor at Lilly Research Laboratories. Dr. Given is the Chairman of VIA Pharmaceuticals, and a member of the board of directors of SemBioSys Genetics and Vivaldi Biosciences. He is also a member of the Visiting Committee to the Division of Biological Sciences and the Pritzker School of Medicine at the University of Chicago and the Johns Hopkins Bloomberg School of Public Health Advisory Board. Dr. Given holds an MD with honors and a PhD from the University of Chicago, and an MBA from the Wharton School, University of Pennsylvania. He was a fellow in Internal Medicine and Infectious Diseases at Harvard Medical School and Massachusetts General Hospital.

Dr. Gordon has been an innovator in the pharmaceutical industry with over 25 years experience developing both new vaccines and companies. While Director for Bacterial and Viral Vaccines Research at Connaught Laboratories in the US and Canada from 1981 through 1987 he invented and brought to licensure the first bacterial conjugate vaccine, for the prevention of H. influenzae b meningitis. Since that time, he has been President and CEO of three publicly held biotechnology companies. Dr. Gordon is currently serving as a member of the US National Vaccines Advisory Committee and as a member of the Board of Trustees of the Sabin Vaccine Institute.

Jaap Goudsmit is Crucell's Chief Scientific Officer and is responsible for all R&D activities. He was our Senior Vice President Vaccine Research from September 2001 till July 2002 and member of our management committee from July 2002 as Executive Vice President Vaccine R&D. Prior to joining Crucell, Dr Goudsmit held various positions at the Academic Medical Center at the University of Amsterdam, and was Chairman of the Research Institute for Infectious Diseases and the Institute for Science Education. Dr Goudsmit has also taught and been a fellow at a number of institutions, such as the National Institutes of Health and New York University. He was founding Chariman of the Scientific Advisory Committee of the International AIDS Vaccine Initiative (IAVI) and the founding Co-Chair of the European Vaccine Effort against HIV/AIDS (EuroVac). In July 2003, Dr Goudsmit was appointed Chairman of the Board of the AIDS Foundation East-West, a NGO focused on AIDS prevention in the countries of the former Soviet Union. Since 1989 he has been a professor at the University of Amsterdam and the Academic Medical Center. He holds a medical degree and a PhD from the University of Amsterdam. Dr Goudsmit is a member of the Management Board of Crucell.

As a scientist-lawyer, Dr. Haanes specializes in advising biotechnology companies on complex legal issues relating to the worldwide protection and enforcement of their intellectual property, especially in the areas of immunology, virology, vaccines, genomics, proteomics, gene therapy, and biotherapeutics. She advises clients on the creation and management of complex international patent portfolios, freedom-to-operate and patentability issues, validity and infringement issues, and due diligence investigations. Dr. Haanes has written and presented lectures on the IP aspects of drug discovery tools, and was a co-author of an Amicus Brief to the United States Supreme Court in Merck v. Integra. Prior to joining Sterne Kessler, Dr. Haanes served as Project Coordinator of the Molecular Vaccines group at a small biotechnology company in Fort Collins, Colorado, where she directed a team of scientists working on the development and testing of viral vector, nucleic acid, and subunit vaccines for use in companion animals.

Mr. Hancock has been involved in the biotechnology industry for the past twenty-five years, having held process development and GMP manufacturing positions at Hybritech, Genetics Institute and, prior to joining Althea Technologies, as Senior Director of Operations at The Immune Response Corporation. He has extensive experience in production of monoclonal antibodies, recombinant proteins, vaccine development and gene therapy product development, and fill/finish operations. Additional areas of expertise include issues related to regulatory compliance, quality assurance and process validation. Mr. Hancock holds a bachelors degree in Microbiology from Miami University.

Anders Hedegaard joined Bavarian Nordic in August 2007. He comes from a position as member of ALK-Abelló’s Corporate Management in charge of Business Operations. Anders Hedegaard’s management career includes executive positions with Aga, Foss and Novo Nordisk. Mr. Hedegaard is Chairman of the Board of Bavarian Nordic Holding Inc., Bavarian Nordic Inc. and BN ImmunoTherapeutics Inc. Mr. Hedegaard received his Master of Science degree in Chemical Engineering from the Technical University of Denmark.

Dr Luc Hessel is Executive Director, Medical and Public Affairs, Europe, at Sanofi Pasteur MSD, the European Joint Venture between sanofi pasteur and Merck & Co., leading companies in vaccines and biotechnology products. From 1986, he worked at sanofi pasteur in clinical research and development of new vaccines and other biopharmaceuticals. He then served as Director of Medical Affairs and Head of the Pharmacovigilance Department between 1992 and 1996. From 1997 to 2001, Dr. Hessel had responsibility for managing the medical function at Sanofi Pasteur MSD, and coordinating the company’s medical and clinical activities. Since April 2002 he has been in charge of medical and public affairs, covering a broad range of activities, including medical expertise for online, new vaccines and relationship with governments and international institutions. Dr. Hessel is currently chairman of the Influenza Pandemic Working Group of the European Vaccine Manufacturers (EVM) a specialised group within the European Federation of Pharmaceutical Industry Associations (EFPIA), and is member of the Biologicals and Vaccines Committee of the International Federation of Pharmaceutical Manufacturers Associations (IFPMA), where he chairs the Influenza Vaccine Supply International Task Force. He has recently been appointed as Chairman of the Human Vaccine Committee of the International Association for Biologicals (IABS).

Doug Holtzman received his Ph.D. in Molecular and Cell Biology from the University of California/Berkeley in 1993 and his M.P.H. in International Health from Harvard University in 2002. His interest in applied molecular research led to an Associate Scientist position at ICOS Corporation in Bothell, WA, where he worked on novel strategies for the development of radiosensitizers as adjuncts to cancer therapy as well as signal transduction studies in T-cells. In 1996 he joined the scientific staff of Millennium Pharmaceuticals in Cambridge, MA, where he led a multi-disciplinary team combining high-throughput sequencing, bioinformatics and wet-lab studies to identify novel protein therapeutics. Following Millennium Pharmaceuticals he spent five years at Microbia, a start-up biotechnology company focused on infectious diseases, first as a Senior Scientist and then as a Principal Investigator. He began his research career at Cold Spring Harbor Laboratories, and he has also been involved in research projects at the University of California/San Francisco, the Massachusetts General Hospital and the Ludwig Institute for Cancer Research in Melbourne, Australia.

Allan Jarvis is currently Senior Vice President, Corporate Development at Aventis Pasteur, a Division of Aventis Pharmaceuticals. In that capacity he is responsible for the Business Development, Strategic Planning and Process Efficiency and Cost Effectiveness functions. He oversees AvP’s worldwide Corporate Development function and is responsible for managing the company’s growth through alliances, joint-ventures, partnerships, mergers, acquisitions, and the licensing of products and technology. Prior to this, he was Vice President, Business Development and Strategy for the Vaccine Business Unit of Wyeth Pharmaceuticals. Allan received his PhD in Molecular Genetics from the University of California and held NIH Post-Doctoral Fellowships from 1976-1980 at Sloan Kettering Cancer Institute and the Worcester Foundation for Experimental Biology. In 1980, he co-founded Damon Biotech, Inc. where he held diverse positions of increasing responsibility from Manager, Molecular Biology to Vice President, Research and Vice President Business Development. From 1990 to 1992, he worked at Abbott Laboratories, Inc., as Director, Business Development. In 1992 he joined Repligen Corp. in the dual role of Vice President, Business Planning for the parent company and Sr. Vice President, Commercial Development for its wholly owned subsidiary, Amira, Inc. His primary areas of business focus include: strategic planning, valuing products and technology, negotiations and partnership management.

David C. Kaslow, M.D. is the Vice President and Franchise Integrator, Infectious Diseases and Vaccines at Merck Research Laboratories. In this role, he is responsible for integrating a variety of early product development activities in small molecules, monoclonal antibodies and vaccines to prevent or treat infectious diseases. From 2001-2006 he was the Chief Scientific Officer at Vical Incorporated. Dr. Kaslow first joined Merck Research Laboratories in 1999 as a Senior Director of Vaccine Research in the Department of Virus and Cell Biology. He later headed the Department of Vaccine Research and Technology at Merck before joining Vical. From 1986 to 1999, he held various tenured senior research positions at the US National Institutes of Health, including Head of the Malaria Vaccine Section, and founder and Head of the Malaria Vaccine Development Unit in the Laboratory of Parasitic Diseases. He has published more than 150 scientific papers, and authored more than 25 review articles or book chapters. He holds or co-holds more than a dozen patents. Dr. Kaslow received his M.D. from the School of Medicine at the University of California, San Francisco, in 1983, and his Bachelor of Science degree from the University of California, Davis, in 1979.

George Kemble was promoted to vice president of research and development and general manager of MedImmune Vaccines, Inc’s California site in August 2004. After working as a staff scientist and senior scientist, Dr. Kemble was promoted to director of research in 1999, and senior director in 2002. Over the past 11 years at MedImmune, he has led several programs including one aimed at developing a vaccine to prevent mental retardation and hearing loss in newborns caused by cytomegalovirus. As principle investigator, Dr. Kemble obtained approximately $1 million in funding through Small Business Innovation Research grants from the National Institutes of Health to conduct this program. Dr. Kemble also continues to lead the research program aimed at understanding the basic mechanisms of attenuation and immunogenicity for MedImmune’s FluMist® vaccine. Dr. Kemble received his B.S. in biology from the University of Santa Clara, his doctorate degree from the Department of Microbiology and Immunology at Stanford University, and completed a postdoctoral fellowship at the University of California, San Francisco in virology and the mechanisms that allow influenza virus entry into cells. Dr. Kemble has published approximately 20 articles in peer-reviewed journals and has received numerous professional awards.

Dr. Richard Klausner was formerly the global health executive director of the Bill and Melinda Gates Foundation’s Global Health program, whose overarching goal is to improve global health equity. Dr. Klausner previously served as director of the National Cancer Institute (NCI), where he led one of the world’s largest research and health agencies, creating successful national and international programs aimed at applying science and technology to improving the public health. Dr. Klausner is currently a Managing Partner of The Column Group, a strategy-based venture fund. In addition, he is engaged as an independent consultant to international governments and biotech companies. Dr. Klausner is well known for his work in cell and molecular biology. Dr. Klausner has served as chief of the cell biology and metabolism branch of the National Institute of Child Health and Human Development. He has served on numerous advisory committees and is the past president of the American Society for Clinical Investigation. He is the author of more than 300 scientific articles and several books, and has received numerous awards and honors. Dr. Klausner has served as a senior fellow at the National Academies of Science, advisor to the presidents of the Academies for counter-terrorism, and liaison to the White House Office of Science and Technology Policy. In addition, Dr. Klausner lead the efforts of the National Academies of Science to write standards for science education for the United States. He is a member of the National Academy of Sciences and the Institute of Medicine and the America Academy of Arts and Sciences.

Ph.D. from the Danish Technological University and in addition has an Industrial Research Degree from the Danish Academy of Technical Sciences, including managerial and intellectual property training. Dr Klysner following held positions at ALK-Abello, Novo Nordisk, Pharmexa and finally at Nordic Vaccine, adding up to 17 years of experience within the biotechnology- and biopharmaceutical industry. As former VP, Director and member of the board for four years at Pharmexa, a public Danish vaccine company, Dr. Klysner has experience with various aspects of public financing in the biotech industry. Dr Klysner is currently CEO of Nordic Vaccine, a small nano-technology based vaccine Development Company based in the Medicon Valley area in Denmark. Nordic Vaccine has over the years successfully raised money from Danish VC’s and industry for its programs and is currently in the process of financing activities that will develop it into a Phase II company over a period of three years.

Dr. Kurilla is the Director of the Office of Biodefense Research Affairs and Associate Director for Biodefense Product Development for the National Institute of Allergy and Infectious Diseases (NIAID). His primary role is to provide overall institute coordination for product development of medical countermeasures against bioterror threats. He received his undergraduate degree in chemistry from the California Institute of Technology. He earned his MD-PhD from Duke University. He took his postgraduate medical training in Pathology at the Brigham & Women’s Hospital in Boston, MA and a postdoctoral fellowship with Dr. Elliott Kieff at Harvard Medical School as a Life Sciences Research Foundation Fellow followed by a Markey Scholar Award. At the University of Virginia, he was an Assistant Professor of Pathology as well as Co-Director of the Laboratory of Molecular Diagnostics and Associate Director for Clinical Microbiology. He moved to the private sector working in anti-infective drug development at Dupont Pharmaceuticals, Bristol-Myers Squibb, and Wyeth. He subsequently joined the National Institute of Allergy and Infectious Diseases (NIAID) as a Medical Officer. In 2005, he was named to his current positions within NIAID.

Clement Lewin is Vice President of Government Affairs and Strategy at Acambis. Prior to taking up his position, Clem was at Chiron Vaccines as Vice President Government Affairs & Immunization Policy for the US and Vice President, Strategic Planning & Business Intelligence for the business unit based at global headquarters in the United Kingdom. Clem obtained his BSc and PhD from the University of London. After 5 years as a Research Fellow at the Universities of London and Edinburgh focusing on mechanisms of action and resistance to antibiotics he obtained an MBA with distinction from Cornell University. He then joined the life sciences practice of Pittiglio Rabin Todd & McGrath specializing in product development issues. Prior to joining Chiron, Clem was with Merck Vaccines Division in a variety of domestic and international marketing positions and with Bayer Pharmaceuticals as Director of Global Scientific Affairs for their anti-infective franchise. He currently serves as the BIO liaison representative to the Advisory Committee on Immunization Practices and on the advisory boards of Bio Ventures for Global Health and the Alliance for Biosecurity.

Michael Lytton joined Oxford Bioscience Partners in January 2001. Prior to that, he was Partner, Chairman of the Technology Group, and a member of the Executive Committee of Palmer & Dodge LLP, a Boston-based law firm. Mr. Lytton serves on the Boards of Directors of Claros Diagnostics, Decision Biomarkers, Enanta, GPC Biotech, Radius, Rib-X, Santhera, and VaxInnate. Mr. Lytton was also responsible for investments by Oxford in Alantos, AVEO and Concentric. Mr. Lytton is Chairman of the Research and Technology Committee of the Immune Disease Institute, Harvard Medical School, where he is also a member of the Board of Trustees. Mr. Lytton also serves on the Board of Directors Medicines in Need, a Harvard-based foundation sponsoring clinical development of novel drug delivery technologies for medicines supplied to developing world countries. Mr. Lytton has served on the Executive Board of the MIT Enterprise Forum and the Patent Committee of the Boston University Medical Center. He has also written many articles over the past decade concerning the biotechnology industry for the Windhover publication, Start-Up magazine. He was a summa cum laude graduate of Princeton University and a recipient of a Fulbright Scholarship for study at the University of London, and he received a J.D. degree cum laude from Harvard Law School. Mr. Lytton also received a M.Sc. degree in Epidemiology and Medical Statistics from the London School of Hygiene and Tropical Medicine.

Dr. Mansoura is the Acting Deputy Director for Policy, Planning, and Requirements in the Office of the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The mission of the ASPR is to lead the nation in preventing, preparing for, and responding to the adverse health effects of public health emergencies, and natural and manmade disasters. BARDA has a leadership and coordinating role in the research, development, and acquisition of vaccines, therapeutics and diagnostics to address Pandemic Influenza as well as Chemical, Biological, Radiological, and Nuclear (CBRN) threat agents.

Dr. Carol A. Marzetta, Vice President, R&D Strategy Services and co-founder of Applied Strategies, specializes in developing and implementing drug and vaccine development strategies, integrating project and line management team processes, and designing portfolio prioritization and resource allocation processes and methodologies in both pharmaceutical and biotech settings. She has nearly 20 years of experience in small molecule and biologic drug development that has spanned from drug discovery to clinical development to launch. She has contributed to the filing of products in the US, EU, and Japan, led drug development teams, and served on senior management committees responsible for strategically managing drug and vaccine development portfolios and operations.

Kelly T. McKee, Jr., M.D., M.P.H., is Executive Director of Operations for Quintiles Transnational Corp’s Public Health and Government Services unit. He has specific expertise in vaccines, emerging diseases, biodefense, respiratory viral infections, and sexually transmitted diseases. Dr. McKee received his medical degree from the University of Virginia School of Medicine, and completed his internship, residency, and fellowship training in Pediatrics and Pediatric Infectious Diseases at Vanderbilt University hospital. He completed a 20 year career in the U.S. Army Medical Department, during which he completed residency training in Preventive Medicine at the Walter Reed Army Institute of Research and received a Masters degree in Public Health from Johns Hopkins University School of Hygiene and Public Health. While in the Army, Dr. McKee held a variety of leadership positions at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) at Fort Detrick, Maryland, and at Fort Bragg, N.C., retiring as a Colonel in 2001. After a brief stint as State Epidemiologist for the State of North Carolina, he returned to Maryland as a Department of Defense contractor supporting the anthrax vaccine immunization program, then accepted a position in 2004 as Senior Director for Clinical Research at DynPort Vaccine Company. He left DynPort in September, 2006, to join Quintiles. Dr. McKee is Board Certified in General Pediatrics, and holds a Certificate of Knowledge in Clinical Tropical Medicine and Traveler’s Health. He has experience in basic and applied, research, and has particular interest in the pathogenesis and epidemiology of infectious diseases. He has served as an investigator in Phase 1, 2, and 3 clinical trials, and as a sponsor in Phase 1 and 2 studies.

Dr. Midthun is the Deputy Director of Medicine in the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration. CBER regulates vaccines, blood and blood products, and cellular, tissue, and gene therapies. Its responsibilities include oversight of the investigational phases of product development, decisions regarding licensure, and post-licensure surveillance activities. Immediately prior to her current position within FDA, she served as Director of the Office of Vaccines Research and Review within CBER. She has published many articles in peer-reviewed journals, and has represented the FDA at many public meetings and interacted with Congress, both at hearings and briefings. Before joining the FDA in 1993, Dr. Midthun was an assistant professor in the Department of International Health at the Johns Hopkins Bloomberg School of Public Health, where she was involved in the clinical development of several investigational vaccines at the Center for Immunization Research. She also was a faculty member of the Division of Infectious Diseases, Johns Hopkins School of Medicine. Dr. Midthun received her bachelor’s degree from the Massachusetts Institute of Technology and her medical degree from the George Washington University School of Medicine. She trained as a resident in internal medicine at Johns Hopkins Hospital and as a fellow in infectious diseases at Johns Hopkins Hospital and the National Institute of Allergy and Infectious Diseases. She is a fellow of the Infectious Diseases Society of American and a member of the American College of Physicians and the American Society for Virology.

Dr. John A. Mikszta is currently Director, Parenteral Technologies at BD Technologies in Research Triangle Park, NC, USA. Dr. Mikszta has over 12 years of experience in the field of drug delivery and has led research and development efforts around alternative delivery systems for vaccines including dermal, nasal, pulmonary and powder formulations technologies. Dr. Mikszta received a Ph.D. degree in Immunology and Molecular Pathogenesis from Northwestern University School of Medicine in 1996. Before joining BD, Dr. Mikszta conducted post-doctoral research in the Department of Immunology at the Duke University Medical School.

Dr. Monath is a Partner, Pandemic and Biodefense Fund, Kleiner Perkins Caufield & Byers. He is also Adjunct Professor, Harvard School of Public Health. Between 1992 and 2006, Dr Monath was Chief Scientific Officer and an Executive Director, Acambis (a publicly traded biopharmaceutical company) where he directed R&D on dengue, West Nile, Japanese encephalitis, yellow fever, Clostridium difficile, and smallpox vaccines for defense against bioterrorism. Monath received his undergraduate degree from Harvard College and M.D. from Harvard Medical School and trained in internal medicine at the Peter Bent Brigham Hospital, Boston. COL Monath retired from the US Army in 1992 after 24 years in the uniformed services. Between 1973-1988, he was Director, Division of Vector-Borne Viral Diseases, Centers for Disease Control, Fort Collins CO and from 1989-92 Chief, Virology Division, US Army Medical Research Institute of Infectious Diseases (USAMRIID). He is on the editorial board of 5 scientific journals. He received the Nathanial A. Young Award (1984), the Richard M. Taylor Award (1996), and the Walter Reed Medal (2002) from the American Society of Tropical Medicine & Hygiene and was President of that Society (2004-05). He has served on numerous government and international committees on infectious diseases, biosecurity, World Health Organization expert committees and the National Vaccines Advisory Committee (USA). Dr. Monath has published over 340 papers and edited 6 books on the epidemiology, immunology and pathogenesis of viruses and on vaccine development.

17 years of experience in finance and CFO for Genome Canada & multiple successful start-ups

Dr Derek O’Hagan is Head of Vaccine Delivery Research and Vice President Novartis Vaccines and Diagnostics, now based in Siena. He previously spent 10 years at Chiron, Emeryville. Past positions that he has held include a lecturer in Drug Delivery, School of Pharmaceutical Sciences, University of Nottingham.

Dr. Ariel Pablos-Méndez joined the Rockefeller Foundation as Managing Director on April, 2007. He is an Associate Professor of Medicine and Public Health at Columbia University in New York.Previously, Dr. Pablos-Méndez served as the Director of Knowledge Management & Sharing at the World Health Organization (WHO) in Geneva, working to help bridge the know-do gap in public health and advancing the field of e-health. He has returned to the Rockefeller Foundation, where he was a program officer from 1998 to 2004 spearheading a program on public-private partnerships in R&D for diseases of poverty and the Foundation's strategy on AIDS and human resources for health. His current work is addressing the global challenge of health systems. Dr. Pablos-Méndez received his M.D. from the University of Guadalajara’s School of Medicine (Mexico) and his M.P.H from Columbia University’s School of Public Health.

Robert is a Co-Founder and Managing General Partner of Lux Capital, focusing on ventures in nanotechnology and life sciences. Robert graduated from the University of Virginia and is a member of the Regional Selection Committee for UVA’s Jefferson Scholars Foundation. Robert is also a member of Motorola's Research Visionary Board and an invited lecturer at the Memorial Sloan-Kettering Cancer Center, the National Cancer Institute, Yale University, University of Washington, and the University of Virginia. He has been published in Journal of Biomedical Materials Research (Applied Biomaterials) and Nature Biotechnology. Robert manages Lux Capital’s investment in Tempo Pharmaceuticals (pharmaceutical nanoencapsulation), Magen Biosciences (dermatology), Molecular Imprints (semiconductor imprint lithography) and Kereos (targeted nanoparticle diagnostics). Robert is a co-founder and Director at Genocea Biosciences (vaccine discovery) and Lux Research (emerging technology research).

Dr. Gregory Poland is the Director of Mayo Clinic’s Vaccine Research Group – a state-of-the-art research group and laboratory that investigates issues surrounding vaccine response and novel vaccines important to public health. Dr. Poland is a Professor of Medicine and Infectious Diseases and Molecular Pharmacology and Experimental Therapeutics, the Associate Chair for Research for the Department of Medicine, the Director of the Immunization Clinic and the Director of the Program in Translational Immunovirology and Biodefense at Mayo Clinic. He also serves as the President of the International Society for Vaccines and the American Editor for the journal “Vaccine.” In March 2005, Dr. Poland was elected as the President of the Armed Forces Epidemiological Board. He was appointed as the Mary Lowell Leary Professor in Medicine (the highest academic distinction for a faculty member) by Mayo Clinic’s Board of Trustees. In May 2003, he was awarded the Secretary of Defense Medal for Outstanding Public Service. Since 2004, Dr. Poland has also served on the Infectious Diseases Society of America (IDSA) Taskforce on Pandemic Influenza. In 2000, he was appointed as the American Editor for the prestigious medical journal Vaccine. In 1998, he received a joint award from the Centers for Disease Control and Prevention and the Health Care Financing Administration for his contribution to increasing adult immunization rates in the U.S. which was awarded by the Surgeon General of the United States. Also of major significance, in 1997, he was honored as the “Outstanding Clinical Investigator of the Year” by Mayo Clinic.

Dr. Douglas Pon is Assistant Vice President, Vaccine Licensing Global Business Development for Wyeth Pharmaceuticals and is based in Collegeville PA. Doug joined Wyeth in January 2006 where he is responsible for the global licensing and business development activities of the Vaccines Business Unit. Doug holds his Ph.D., M.Sc. and B.Sc. degrees in Pharmacology from the University of Toronto. In 1990, following a postdoctoral fellowship in molecular endocrinology at the Banting and Best Department of Medical Research, Doug joined Merck Frosst Canada, Inc. After ten years of discovery research in respiratory disease, Doug moved to External Scientific Affairs in West Point PA where he was Director Scientific Liaison responsible for identification, evaluation, and negotiation of licensing and collaborative research opportunities for Merck Research Laboratories (MRL) in several therapeutic areas, including Oncology, Urology, Vaccines, Biologics and Antibodies, Anti-Virals, and Vaccine Adjuvants/Delivery Systems.

Dr Hélène Pora is Vaccine Application Development director with Pall LIfe Sciences , where she has the worldwide responsibility for the development of improved separation and purification solutions for the vaccine and gene therapy market. She is also heavily involved in the development of improved single use technologies and related scale-up aspects. Hélène has more than 20 years of experience working for the pharmaceutical and the separation industries, the last 15 years with Pall Corporation. She holds an Engineering Degree in Biochemistry (with Molecular Biology) from the Institut National Agronomique (France) and a PhD in Biochemistry ( on protein engineering and purification) from the University of Orsay (France). Hélène Speaks regularly at conferences about improved separation technologies for the biotechnology and biopharmaceutical industry.

Frank Rapoport develops and helps implement business plans focusing on government contracts for companies in the public health, biodefense/vaccine, medical supply and logistics, construction, engineering, information technology, transportation, biotech, and pharmaceutical. His practice focuses on government contracts and public health law. Frank is a leader in the growing field of public health contracting and Biodefense procurement and has testified before two Congressional Committees-House Government Reform and House Selection on Homeland Security-on how to build a Biodefense industry. He coordinates Biodefense Connection™ which serves as a clearing house of scientific legal, government affairs and venture capital needs of pharmaceutical and biotech companies interested in securing funds from the National Institutes of Health, Centers for Disease Control, Department of Defense, the Department of Health and Human Services, and Department of Homeland Security.

Dr.G.S.Reddy is the General Manager (Manufacturing) of Human Biologicals Institute, a Division of Indian Immunologicals Limited, a major veterinary and human vaccines manufacturer in India. He obtained basic degree in Veterinary medicine in 1981 from Andhra Pradesh Agricultural University, Hyderabad. He has 22 years of experience in industry, developing veterinary and human biologicals. Experience encompasses Quality, Research and Development, Manufacturing and regulatory affairs. He is heading the team which is involved in manufacturing of recombinant hepatitis B, Measles, DPT, TT, DT and DPTH vaccines. He worked on collaborative vaccine development projects with Georg August University, Gottingen, Germany and Centers for Disease Control and Prevention, Atlanta, USA. He is co-author of patent on DNA Rabies vaccine. He has published 40 scientific papers in various journals.

Dr. Robinson is the Director for the Pandemic Influenza Program for the Biomedical Advancement Research and Development Authority (BARDA) in Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Dr. Robinson joined HHS in May 2004. Dr. Robinson oversees a staff of 17 scientists and analysts in Washington, D.C., who are implementing medical countermeasure action items of the HHS Pandemic Implementation Plan to develop, acquire, and expand production of pandemic vaccines and antiviral drugs. For the Department Dr. Robinson serves as a subject matter expert for pandemic influenza including viral disease, vaccine development, manufacturing, industrialization, and stockpiling. For the HHS Secretary and Undersecretaries he prepares briefings on pandemic influenza, options and recommendations on national policy and budget issues relative to seasonal and pandemic influenza. Further, he provides the Department with scientific, technical, and budgetary guidance on pandemic and interpandemic influenza medical countermeasure and coordinates interagency programs for acquisition and deployment of influenza vaccines and antiviral drugs under special case IND.

Mr. Rona brings over 15 years experience in originating, structuring and executing corporate transactions and financings. Most recently, Mr. Rona was Vice President of Corporate Development for Corgentech, Inc. following the merger between Corgentech and AlgoRx Pharmaceuticals in late 2005. Prior to the merger, Mr. Rona was the Chief Financial Officer of AlgoRx, and was responsible for the execution of the merger with Corgentech. Mr. Rona also led AlgoRx $65 million Series C financing in early 2004. Prior to joining AlgoRx in 2002, Mr. Rona was in the Investment Banking department at UBS Warburg. Mr. Rona has also served as the director of finance and corporate development at Antigenics, taking the Company public in early 2000. Mr. Rona started his career at Coopers & Lybrand where he spent seven years serving clients needs in accounting, tax and corporate finance. Mr. Rona received a B.S. in Accounting from Case Western Reserve University in 1990.

My position is director of External Research and Development (ER&D) in sanofi pasteur the vaccine division of sanofi aventis. The ER&D team is headed by Jeffrey Almond and is positioned at various sites around the globe including the United States, Canada, France, India and China. The ER&D team works closely with our Business Development Group by evaluating the scientific merit of potential external collaborators. Prior to this position, I worked in Research where I led the development of our meningococcal conjugate vaccine, now licensed in the United States and Canada under the trade name, Menactra. I obtained my PhD in chemistry from the The Pennsylvania State University, and was a post-doctoral fellow at Northwestern University prior to joining sanofi pasteur.

Una S. Ryan, Ph.D., O.B.E. is President and CEO of AVANT Immunotherapeutics, Inc., a publicly traded biopharmaceutical company developing vaccines and immunotherapeutics for cardiac surgery, cholesterol management, biodefense, travelers, food safety, and global health. AVANT is developing a portfolio of oral vaccines designed to provide rapid protection following a single dose. AVANT’s rotavirus vaccine is marketed by GlaxoSmithKline Biologicals as Rotarix® in the European Union and over 65 countries. Dr. Ryan has led the expansion of AVANT’s vectored bacterial vaccines programs, completed three company acquisitions, and established the company’s new manufacturing facility in Fall River, Massachusetts. She is also Research Professor of Medicine at the Boston University School of Medicine and serves on its Board of Visitors. She is immediate past Chair of the Massachusetts Biotechnology Council, serves on its Board, as well as the Boards of the Biotechnology Industry Organization, the New England Healthcare Institute, the Board of Associates of the Whitehead Institute, and the Board of Directors of IQuum, Inc. Dr. Ryan is a member of the Strategy & Policy Council of the MIT Center for Biomedical Innovation and serves as a member of the Business Advisory Board of BIO Ventures for Global Health. In 2002 Her Majesty Queen Elizabeth II awarded Dr. Ryan the Order of the British Empire (OBE) for her services to the research, development and promotion of biotechnology.

Dr. Salmon is a Vaccine Safety Specialist in the National Vaccine Program Office, Office of Public Health and Science, Department of Health and Human Services. He is responsible for coordinating federal vaccine safety activities across Agencies within the Department. Dr. Salmon received his bachelor’s degree from Rutgers University, Masters in Public Health from Emory University, and doctorate from Johns Hopkins University Bloomberg School of Public Health. His research, practice and policy work has focused on vaccine safety, compulsory vaccination, and factors impacted parental acceptance and refusal of vaccines.

Joe Santangelo is a founder, board member and Development Director of SingVax Pte. Ltd (incorporated in 2004), which is a privately held Singapore biotech company focusing on vaccines for human health. His responsibilities at SingVax include management of all development operations as well as defining the corporate product development strategies. Prior to this he served in R&D roles at Microscience Ltd. from its inception as a spin out from Imperial College of Science Technology and Medicine (UK) in 1997. His overall career in microbiology, infectious diseases and fermentation spans more than 25 years. Joe was born, educated and worked in the United States, before moving to South Africa, Germany, the United Kingdom and Singapore. He has worked in both academia and industry, and moved to the biotech sector 10 years ago. Joe has a B.Sc. from the State University of New York, an M.Sc. from the University of Vermont and a Ph.D. from the University of Cape Town. He was awarded an Alexander von Humboldt fellowship (1993) and is a member of various Microbiology and Biotechnology Societies.

Dr. Shaw joined VaxInnate from the Merck Vaccine Research Division where he was Executive Director of MVD’s Public Policy, Public Health and Medical Affairs Department. Prior to this, he was the Executive Director of Virus & Cell Biology at Merck Research Laboratories, responsible for all the aspects of live virus vaccine research, as well as technical aspects of development and production. His responsibilities covered research and early development of recombinant protein-based vaccines. Dr. Shaw was instrumental in the development of a combination measles-mumps-rubella-varicell vaccine (ProQuad®), a live oral rotavirus vaccine, (RotaTeq®), human papillomavirus vaccine (Gardasil®), and the candidate zoster vaccine (Zostavax®) as well as numerous early-stage experimental vaccines. He has over 15 years of experience in the development, testing manufacturing, and implementation of vaccines in the United States, Europe and in international programs. Prior to joining Merck, Dr. Shaw worked on vaccines for hepatitis B and Plasmodium falciparum as well as cytokines, cell trafficking and natural inhibitors of inteleukin-1 at Biogen, SA in Geneva, Switzerland.

Dr. John Shiver is Vice President, Worldwide Basic Research Franchise Head, Vaccines, at Merck Research Laboratories in West Point, Pennsylvania, USA. Dr. Shiver is responsible for the worldwide leadership of vaccine basic research for the Infectious Diseases Franchise leading the teams of scientists working to develop novel vaccines against a broad range of diseases, including HIV/AIDS, human papillomavirus, rotavirus, zoster, influenza and bacterial infections. Dr. Shiver has gained international recognition in the scientific community for his leadership of Merck’s novel HIV vaccine research program. He has led Merck’s HIV-1 vaccine research team since 1992 playing an instrumental role in the development of vaccines based on gene delivery technologies and of quantitative immunological assays to measure T cell immune responses. Most recently, he was named as one of the “Top 20 Southerners to Watch” by The Financial Times for his extensive contributions to HIV/AIDS vaccine research.

Dr. Siber joined Wyeth Vaccines as Vice President and Chief Scientific officer in 1996. He was named Executive Vice President in June, 2002. While at Wyeth, Dr. Siber has overseen the development and approval of multiple widely used childhood vaccines including an acellular pertussis vaccine (Acel-Imune), a meningococcal meningitis vaccine (Meningitec), and a pneumococcal vaccine (Prevnar). Prior to joining Wyeth Dr. Siber was Director of the Massachusetts Public Health Biologic Laboratories and Associate Professor of Medicine at the Harvard Medical School’s Dana Farber Cancer Institute. During this time Dr. Siber oversaw research and manufacturing of multiple vaccines and immune globulins. On May 12th, 2006 the recently completed $100 Million Massachusetts Biologic Laboratory building for vaccine development and manufacturing was dedicated to Dr. Siber and his colleague Dr. Jeanne Leszczynski in recognition of their R & D contributions which enabled the establishment of this facility. Dr. Siber has authored more than 150 scientific articles in peer-reviewed journals and holds three issued patents.

Ph.D. Biochemical Pharmacology, 15 years in product development and regulatory affairs. Consultant to industry the last 5 years in product development, IT and regulatory/compliance.

Dr. Rahul Singhvi was appointed President and CEO of Novavax in August, 2005. He joined the Company in April, 2004 as Vice President, Pharmaceutical Development and Manufacturing Operations and was appointed Senior Vice President and Chief Operating Officer in April, 2005. He is charged with restructuring the company to focus on its core competency of new product development and innovation and drive shareholder value. Prior to joining Novavax, Dr. Singhvi spent 10 years with Merck & Co, most recently serving as Director of Vaccine and Sterile Operations in the Merck Manufacturing Division. In this position Dr. Singhvi was responsible for operating a manufacturing unit producing a new biological product and initiating the start up of a second biological product manufacturing unit. In addition to his functional expertise within process development and manufacturing, Dr. Singhvi was a recognized leader within Merck & Co., Inc. for the depth and breadth of his expertise, and led several cross-functional teams responsible for technology transfer and development of new products. Dr. Singhvi holds several patents in the area of cell culturing systems and has co-authored numerous publications, book chapters, and abstracts on biochemical engineering and cell physiology.

-Special Advisor on Influenza Pandemic Vaccine Development; WHO Initiative for Vaccine Research, Jan 2006-Jan 2007 -Coordinator/Project Leader, WHO Global Influenza Programme, 2001-Jan 2006 -Coordinator, SARS Aetiology and Diagnosis, WHO, Feb 03 to July 03 -Scientist, Animal and Food related Public Health Risks, Department of Communicable Diseases, WHO, 1998-2001 -Scientist, Zoonotic Disease Unit, Division for Emerging and Other Communicable Diseases, WHO, 1995-1998 -Scientist, Veterinary Public Health Unit, Div Communicable Diseases, WHO, 1991-95 -Head, Department of Infectious Diseases, National Institute for Epidemiology and Infectious Disease Control in Animals, Germany1989-1991 -Scientist, Department of Infectious Diseases, National Institute for Epidemiology and Infectious Disease Control in Animals, Eastern Germany, 1987-1989 -Research Fellow, Department for Epidemiology and Veterinary Public Health, Faculty Veterinary Medicine, University Leipzig, Eastern Germany, 1984-1987

Erich Tauber is responsible for Product Development and Medical Affairs for Intercell. In his role he oversees functions including Clinical Development, Project Management and Regulatory Affairs. Before joining Intercell, he had various responsibilities with Baxter and AstraZeneca. Erich Tauber has been trained as paediatrician at the Universities of Vienna and Southampton

As senior vice president of MedImmune Ventures, Inc., Dr. Top identifies companies that may be suitable for partnership and investment opportunities. He also serves as medical counsel to the clinical development group at MedImmune, Inc. Dr. Top is currently a board member of VaxInnate, Inc., Applied Genetic Technologies Corporation and GlycoMimetics, Inc. and previously Avidia, Inc. Dr. Top joined MedImmune in June 1988 as executive vice president and was elected to the board of directors where he served from 1988 to 2003. He became the company’s medical director in 1990, and held that position until he was appointed senior vice president of MedImmune Ventures in July 2004. Prior to joining MedImmune, Dr. Top served as senior vice president for clinical and regulatory affairs at Praxis Biologics from 1987 to 1988. Prior to 1987, Dr. Top served for 22 years in the U.S. Army Medical Research and Development Command, where he was appointed Director and Commandant, Walter Reed Army Institute of Research, in 1983.

Dr Tevi D Troy is the Deputy Secretary of Health and Human Services, the chief operating officer of the largest civilian department in the federal government, with a budget of $640 billion and 65,000 employees. Working closely with Secretary Mike Leavitt, Troy oversees all operations, including Medicare, Medicaid, public health, medical research, food and drug safety, welfare, child and family services, disease prevention, Indian health, mental health services, and many other activities. He also serves as the Regulatory Policy Officer for HHS, overseeing the development and approval of all HHS regulations and significant guidance.

Dr. Jeffrey Ulmer received his B.Sc. with honors from the Department of Chemistry at the University of Regina in 1978 and was the recipient of the Merit Award of the Society of Chemical Industry. He received his Ph.D. in biochemistry from McGill University in 1985 and completed his postdoctoral training in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine. At Merck Research Laboratories he conducted seminal studies on DNA vaccines, and is currently Head, Immunology & Cell Biology at Novartis Vaccines and Diagnostics. His group is responsible for discovery and technology development of vaccines and adjuvants; and production, purification, and characterization of recombinant protein-based vaccines. He has published over 150 scientific articles, is on the editorial boards of Expert Opinion on Biological Therapy and Human Vaccines, and is on the Scientific Advisory Committee of the Duke University Multiscale Integrative Immunology for Adjuvant Development program.

Brian focuses on investments in North American therapeutics companies at all stages of development. With over 12 years of investment and operational experience in the biopharmaceutical sector, he has been a key player in the growth of over 10 life science companies in Canada and the US. Located in our Toronto office, Brian joined our firm in 1997. Before joining Lumira Capital, Brian was assistant vice president research Pasteur Mirieux Connaught (PMC) from 1994 to 1997, where he was responsible for the Canadian Universities Research program and several global vaccine development programs. During his academic career, Brian was associate dean, research at the University of Toronto’s Faculty of Medicine and at the Faculty of Health Sciences at McMaster University. Brian has published over 85 articles in immunology in numerous peer review publications. Brian obtained his PhD in immunology from McGill University at Montréal, Québec, and undertook post-doctoral studies at Washington University School of Medicine at St. Louis, Missouri, where he focused on immune-mediated diseases and vaccine development.

CEO of Vaxin Inc. . Dr. Van Kampen has been CEO of several biotechnology companies including Virogenetics, a Division of Aventis Pasteur, the largest vaccine company in the world. While leading Virogenetics, the Division created multiple recombinant vaccines that are currently licensed in the veterinary market. Dr. Van Kampen brings a wealth of experience in the field of vaccinology, especially in research, development and commercialization. Earlier in his career, Dr. Van Kampen was the Department Head of Veterinary Sciences at Utah State University and Director of Physiological Research at Medtronic. He serves on the Boards of Vaxin Inc., HMV Corp., ImmunoMed Corp. and The Van Kampen Group Inc.

Dr. Kimberlee Wallace is the Director of GMP Operations and Process Research for the Vaccine Research Center (VRC) at the National Institutes of Health (NIH). She is responsible for the development of scalable, GMP-compliant manufacturing processes for vaccines, technology transfer of production processes and manufacture of investigational vaccine candidates.

Pierre joined SynCo in June 2000 and is responsible for the overall management of the company. He brings to the company over 15 years of successful financial management and restructuring experience, in the pharmaceutical and graphic arts industries. Previously, Pierre held financial and project management positions with Chiron, Centocor and Kodak Polychrome Graphics. He received an MBA from the Business School Nederland, Buren and holds a bachelors degree in Business Economics from the Higher Institute of Business and Economics, Amsterdam, The Netherlands. .

Mike Watson is a UK physician with a clinical background in gastroenterology and infectious diseases and is a member of the Royal College of Physicians and the Faculty of Pharmaceutical Medicine. He has worked in pharmaceutical development since 1993 and since 1998 in vaccines. He spent 9 years with Sanofi Pasteur MSD, firstly as UK Medical Director and subsequently as Director of Clinical Development and Epidemiology based in Lyon, France. He led the teams that developed and licensed Pediacel® in the UK and Gardasil™ (Quadrivalent 6,11,16,18 HPV vaccine) in Europe and has worked on all almost all classes of vaccines. He is on the editorial board of the Journal of Clinical Virology and is an associate editor of Human Vaccines. He has als